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ABSTRACT 
Aims:  Trebananib, a peptide-Fc fusion protein, inhibits angiogenesis by inhibiting binding of 
angiopoietin-1/2 to the receptor tyrosine kinase Tie2.  This randomized, double-blind, placebo-
controlled phase 3 study evaluated whether trebananib plus pegylated liposomal doxorubicin 
(PLD) improved progression-free survival (PFS) in patients with recurrent epithelial ovarian 
cancer. 
Methods:  Women with recurrent ovarian cancer (platinum-free interval ≤12 months) were 
randomized to intravenous PLD 50 mg/m2 once every 4 weeks plus weekly intravenous 
trebananib 15 mg/kg or placebo.  PFS was the primary endpoint; key secondary endpoints were 
objective response rate (ORR) and duration of response (DOR).  Owing to PLD shortages, 
enrollment was paused for 13 months; the study was subsequently truncated.  
Results:  Two hundred twenty-three patients were enrolled.  Median PFS was 7.6 months 
(95%CI, 7.2─9.0) in the trebananib arm and 7.2 months (95%CI, 4.8─8.2) in the placebo arm, 
with a hazard ratio of 0.92 (95%CI, 0.68─1.24).  However, because the proportional hazards 
assumption was not fulfilled, the standard Cox model did not provide a reliable estimate of the 
hazard ratio.  ORR in the trebananib arm was 46% versus 21% in the placebo arm (odds ratio, 
3.43; 95%CI, 1.78‒6.64). Median DOR was improved (trebananib, 7.4 [95%CI, 5.7‒7.6] months; 
placebo, 3.9 [95%CI, 2.3‒6.5] months).  Adverse events with a greater incidence in the 
trebananib arm included localized edema (61% versus 32%), ascites (29% versus 9%), and 
vomiting (45% versus 33%).  
Conclusions:  Trebananib demonstrated anticancer activity in this phase 3 study, indicated by 
improved ORR and DOR.  Median PFS was not improved.  No new safety signals were 
identified. 
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HIGHLIGHTS 
 Trebananib + PLD did not meet the primary endpoint of improving PFS 
 However, trebananib + PLD improved objective response rate and duration of response 
 No new safety signals were identified in the ENGOT-ov-6/TRINOVA-2 study 
 
Key Words:  ENGOT-ov-6/TRINOVA-2, trebananib, pegylated liposomal doxorubicin, 
progression-free survival, objective response rate, duration of response 
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INTRODUCTION 
First-line platinum/taxane therapy is effective in the treatment of ovarian cancer [1].  
However, the risk of recurrence is high, and outcomes for these patients are poor [2,3].  For 
patients with recurrence following first-line platinum-based therapy, pegylated liposomal 
doxorubicin (PLD) represents an effective nonplatinum second-line therapy [4-8].  All patients 
will experience disease progression, underscoring the need to improve outcomes. 
Angiogenesis is a multifactorial process that plays a key role in tumor growth, 
development, and metastasis [2].  Two distinct pathways are important regulators of 
angiogenesis:  the VEGF pathway and the angiopoietin-Tie2 receptor axis [9-11].  Agents 
targeting the VEGF pathway have been shown to improve progression-free survival (PFS) in 
patients with ovarian cancer but have not been shown to prolong overall survival (OS) [12-20].  
Preclinical studies support the angiopoietin pathway as an important target in ovarian cancer 
[11].  Angiopoietin-1 and angiopoietin-2 regulate angiogenesis and vascular remodeling both in 
normal ovarian physiology and in tumors [11]. 
Trebananib (AMG 386) is a peptide-Fc fusion protein that binds angiopoietin-1 and 
angiopoietin-2, preventing their interaction with the Tie2 receptor [21,22].  In a phase 1b study, 
trebananib plus either PLD or topotecan was tolerable in patients with recurrent ovarian cancer, 
with evidence of antitumor activity [23].  Trebananib combined with weekly paclitaxel has shown 
antitumor activity in women with recurrent ovarian cancer [24,25].  The primary objective of the 
phase 3 Trebananib in Ovarian Cancer-2 (TRINOVA-2) study was to evaluate PFS in patients 
with platinum-resistant or partially platinum-sensitive (platinum-free interval [PFI] ≤12 months) 
recurrent ovarian cancer receiving PLD in combination with trebananib or placebo. 
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METHODS 
Patients 
Eligible patients had epithelial ovarian, peritoneal, or fallopian tube cancer with 
radiographic evidence of disease progression on or following their last dose of prior 
chemotherapy (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 [26]), 
had received one prior platinum-based chemotherapeutic regimen for management of primary 
disease with a PFI ≤12 months, and could have received ≤2 additional cytotoxic regimens for 
recurrent/persistent disease.  Patients were excluded if they had an ECOG performance status 
≥2; previously received PLD or anthracycline/mitoxantrone-based chemotherapy; received 
trebananib or another inhibitor of angiopoietins/Tie2; received radiotherapy within 14 days; 
previous abdominal/pelvic radiotherapy; arterial/venous thromboembolism or clinically 
significant cardiovascular disease within 12 months; clinically significant bleeding within 6 
months; CNS metastasis; nonhealing wound, ulcer, or fracture; higher-than-average risk of 
bowel perforation; or inadequate renal, hematologic, hepatic, or cardiovascular function.  The 
protocol was approved by each center’s independent ethics committee; patients provided 
written informed consent. 
Study Procedures 
This randomized, double-blind, phase 3 study was conducted at 69 sites in 16 countries, 
in collaboration with ENGOT (model C) [27].  Patients were randomized 1:1 to receive 
intravenous PLD 50 mg/m2 once every 4 weeks plus intravenous trebananib 15 mg/kg once 
weekly or intravenous placebo once weekly.  Randomization was stratified by PFI (≥0−≤6 
versus >6−≤12 months), measurable disease (presence/absence), and geographic region 
(North America versus Western Europe/Australasia versus rest of world).  Study treatment 
continued until disease progression, unacceptable toxicity, or withdrawal of consent.  If toxicity 
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occurred, dose modifications for PLD were permitted (to 40 mg/m2 and then 30 mg/m2 for 
palmar-plantar erythrodysesthesia or stomatitis; to 37.5 mg/m2 and then 25 mg/m2 for other 
toxicities).  Dose reductions for trebananib/placebo were not permitted. 
 The primary endpoint was PFS (time from randomization to radiographic disease 
progression per investigator by RECIST or death from any cause). Subjects not meeting these 
criteria at the analysis date were censored.  Key secondary endpoints were OS (time from 
randomization to death), objective response rate (ORR), change in tumor burden, duration of 
response, and incidence of adverse events (AEs). 
Enrollment began on April 18, 2011.  Due to a global shortage of PLD, enrollment in the 
study was suspended from November 23, 2011, to January 10, 2013.  On October 23, 2013, 
Amgen closed the study to patient screening, and the last patient was enrolled on November 12, 
2013.  In total, 223 patients were enrolled. 
Assessments 
Computed tomography or magnetic resonance imaging of at least the chest, abdomen, 
and pelvis was done before cycle 1 and every 8 weeks for the first 64 weeks after 
randomization, then every 16 weeks for 32 weeks, and every 24 weeks thereafter.  Response 
was assessed by investigators per RECIST version 1.1.  AEs occurring from start of treatment 
until the safety follow-up visit (30−37 days after last dose) were graded using the Common 
Terminology Criteria for Adverse Events, version 3.0 [28].  Health-related quality of life (HRQoL) 
was evaluated using Functional Assessment of Cancer Therapy–Ovary (FACT-O), FACT-O 
ovarian cancer subscale (OCS), EQ-5D or EQ-5D VAS [29,30]. 
Statistical Analysis 
Enrollment was initially planned for 380 patients.  At the time the study was closed to 
further enrollment, 223 patients had been enrolled.  After this truncation, the statistical analysis 
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plan was adjusted so that the primary analysis of PFS occurred after 170 patients had PFS 
events; the original methods of statistical analysis were maintained.  With 223 patients and 
assuming median PFS of 7.6 months for trebananib plus PLD and 5 months for placebo plus 
PLD (52% relative improvement; hazard ratio [HR], 0.66), the study had 80% statistical power to 
detect a reduction in the hazard of progression/death while limiting the overall one-sided type I 
error to 2.5%. 
PFS and OS (contingent on positive PFS outcome) were evaluated on an intent-to-treat 
basis.  ORR was evaluated for randomized patients with ≥1 measurable lesion.  Duration of 
response was evaluated in patients who had an objective response.  Safety analyses included 
patients who received ≥1 dose of trebananib/placebo or PLD and were summarized by 
treatment received. 
PFS and OS were evaluated using log-rank tests stratified by randomization factors.  A 
stratified Cox regression model was used to provide estimated HRs and two-sided 95% CIs.  
Nonproportionality of hazards between treatment groups was assessed by comparing the 
standardized Martingale residuals over time to normal distribution [31]; if this comparison was 
significant at the 5% level, a piecewise Cox model was used for analysis.  An exact Cochran-
Mantel-Haenszel test was used for analysis of ORR; the P value from this test was descriptive. 
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RESULTS 
Patient Demographics and Clinical Characteristics 
Two hundred twenty-three patients were randomized (trebananib, n=114; placebo, n=109; 
Figure 1).  The baseline characteristics were generally balanced across treatment arms with 
only minor variations (Table 1).  Median number of cycles of trebananib was 6.0 (range, 1─19); 
median number of cycles of placebo was 5.0 (range, 1─38).  Median number of cycles of PLD 
administered was 6.0 (interquartile range, 3─7; range, 1─19) in the trebananib arm and 4.0 
(interquartile range, 2─6; range, 1─18) in the placebo arm.  Median relative dose intensities for 
PLD were 87.7% and 90.3% in the trebananib and placebo treatment arms, respectively.  At the 
time of this analysis (cutoff date, August 29, 2014), 16 patients continued on treatment 
(trebananib, n=8; placebo, n=8). 
Progression-Free Survival 
After a median follow-up time of 12.4 months (interquartile range, 8.2‒15.5 months), 93 patients 
in the trebananib arm and 89 in the placebo arm had PFS events.  Trebananib did not 
significantly prolong PFS: median PFS for the intent-to-treat population was 7.6 months (95%CI, 
7.2─9.0) for trebananib and 7.2 months (95%CI, 4.8─8.2) for placebo (Figure 2A).  A Cox 
proportional hazards model yielded an HR of 0.92 (95%CI, 0.68‒1.24, P=0.57), but because the 
proportional hazards assumption was not fulfilled this model did not provide a reliable estimate 
of treatment effect.  Instead, a prespecified piecewise Cox model for PFS using 16-week 
intervals was used.  This piecewise model provided further evidence of the non-proportionality 
of hazards: HRs ranged from 0.59 from 0‒16 weeks to 2.38 at 64 weeks and later (Table 2).   
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Secondary Endpoints 
Trebananib plus PLD improved ORR compared with placebo plus PLD.  Among patients with 
measurable disease, 46/99 (46%) in the trebananib arm had an objective response versus 
20/94 (21%) in the placebo arm (odds ratio, 3.43; 95%CI, 1.78‒6.64; stratified Cochran-Mantel-
Haenszel test, P<0.001; Table 3).  Odds ratios for trebananib versus placebo arms were 
generally similar across subgroups, including those defined by the stratification factors (Figure 
3B).  Notably, the odds ratio more strongly favored the trebananib arm among patients with 
ascites at baseline (10.55; 95%CI, 2.26‒49.27) versus those without ascites at baseline (2.32; 
95%CI, 1.09‒4.94).  Among patients with an objective response, the median durations of 
response (95%CI) in the trebananib and placebo arms were 7.4 (5.7‒7.6) and 3.9 (2.3‒6.5) 
months, respectively (Figure 3A).  Overall, 78/99 patients in the trebananib arm and 63/94 
patients in the placebo arm had a decrease from baseline in the sum of the longest diameters of 
target lesions (Figure 3C). 
At the time of analysis, 104 patients (47%) had died.  In a descriptive analysis, median 
OS was 19.4 months (95%CI, 14.9‒22.6) in the trebananib arm and 17.0 months (95%CI, 12.9‒
24.4) in the placebo arm (HR, 0.94; 95%CI, 0.64‒1.39, Figure 2B).  Finally, trebananib 
treatment was not associated with a decrement in HRQoL when compared to placebo 
(Supplemental Figure 1).   
Adverse Events 
All patients who received ≥1 dose of study treatment (trebananib, n=113; placebo, 
n=108) experienced ≥1 treatment-emergent AE.  The incidence of AEs of grade ≥3 was 77% 
versus 72% among those who received trebananib and placebo, respectively.  The incidence of 
fatal AEs was 6% in the trebananib arm and 7% in the placebo arm.  Two patients in each arm 
had fatal AEs considered possibly related to trebananib/placebo (trebananib:  cerebral ischemia, 
right ventricular failure; placebo:  pulmonary embolism, respiratory failure).  AEs leading to 
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discontinuation of trebananib/placebo occurred in 27% of patients who received trebananib and 
21% of patients who received placebo.  AEs leading to discontinuation of PLD occurred in 18% 
of patients who received trebananib and 23% of patients who received placebo. 
AEs with a greater incidence in the trebananib arm included localized edema (61% 
versus 32%), as well as ascites (29% versus 9%), vomiting (45% versus 33%), hypokalemia 
(21% versus 10%), fatigue (53% versus 44%), and cough (20% versus 15%) (Table 4).  
Mucosal inflammation (18% versus 24%), abdominal pain (31% versus 38%), and neutropenia 
(13% versus 20%) occurred with greater incidence among patients who received placebo.  
Grade 3 edema events occurred in five patients who received trebananib and two patients who 
received placebo; there were no grade ≥4 edema events.  Seven patients discontinued 
treatment due to edema (trebananib, n=5; placebo, n=2).  Blurred vision occurred in 5% of 
patients who received trebananib and 3% of patients who received placebo.  AEs previously 
associated with anti-VEGF antiangiogenic agents [32] did not occur with greater incidence 
among patients who received trebananib versus placebo; these included hypertension 
(trebananib, 11% versus placebo, 8%), arterial thrombotic events (1% in both patient groups), 
proteinuria (5% versus 4%), impaired wound healing (2% versus 7%), gastrointestinal 
perforations (1% versus 0%), and venous thromboembolic events (11% versus 8%). 
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DISCUSSION 
Trebananib in combination with weekly paclitaxel has previously been shown to 
significantly improve PFS compared with placebo plus paclitaxel in women with recurrent 
ovarian cancer [25].  Consistent with this evidence, we found that trebananib plus PLD 
demonstrated anticancer activity, as shown by clinically meaningful improvements in ORR (46% 
versus 21%) and duration of response (7.4 months versus 3.9 months) for patients who 
received trebananib.   
Despite this evidence of antitumor activity the planned statistical analysis did not reveal 
an improved PFS in the trebananib plus PLD arm versus the placebo plus PLD arm (the primary 
endpoint was not met).  A requirement for the estimation of HRs using Cox models is that the 
risks of progression must remain proportional over time.  However, this assumption was not 
met, and the planned method of analysis could not yield a reliable estimate of the treatment 
effect.  Because the overall Cox model was thus not an appropriate method of analysis, we 
used a prespecified piecewise Cox model to evaluate PFS at 16-week intervals.  Although there 
appeared to be a risk reduction in patients in the trebananib arm during the initial phase of the 
study, this treatment effect was not maintained after 16 weeks.  Certain aspects of study 
conduct may have contributed to these results.   Enrollment was temporarily halted for 14 
months because of shortage of PLD.  This enrollment hold resulted in two time-separated study 
cohorts, with different median actual follow-up times.  Additionally, there were marked 
differences in exposure to PLD within treatment arms that were not anticipated before the study 
began.  Continuation of PLD beyond six cycles of treatment (the minimum number of planned 
treatment cycles) was at the discretion of the investigator.  Notably, a considerable proportion of 
patients received longer exposure to PLD (>6 cycles).  This broad range of treatment intensity 
with PLD within each treatment arm made comparisons between the arms challenging.  
Together, these study-related factors may have affected the proportionality of risk of progression 
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over time and obscured any treatment effect on PFS.  Notably, ORR—which is not a time-to-
event endpoint and therefore may not have been confounded to the same extent as PFS—was 
46% in the trebananib arm versus 21% in the placebo arm.  Although the original enrollment 
target was not met, it appears unlikely that lack of statistical power was a primary driver for the 
failure to meet the primary endpoint.   
The addition of trebananib to PLD did not result in an increase in the incidence of grade 
≥3 AEs; no new safety signals associated with trebananib treatment were identified.  As 
reported in other studies [25], edema events (in particular localized edema) occurred more 
frequently among patients who received trebananib; however, few patients (4%) had grade 3 
edema and few discontinued owing to edema.  The combination of trebananib and PLD did not 
result in exacerbation of toxicities associated with PLD (eg, palmar-plantar erythrodysesthesia). 
Our results show that trebananib has incremental antitumor activity in combination with 
PLD, in terms of ORR and DOR, a finding that is consistent with previous studies that have 
demonstrated clinical activity of antiangiogenic agents in women with recurrent ovarian cancer.  
Combining anti-VEGF agents with chemotherapy has shown activity in this setting, although 
demonstrating robust improvements in outcomes has been challenging [12,13,19,33].  In the 
AURELIA trial, median PFS was significantly improved in the bevacizumab plus PLD group, 
whereas ORR and OS were not [34].   In the OCEANS study, addition of bevacizumab to 
chemotherapy improved PFS and ORR, but not OS [13,20].  In the ICON6 phase 3 trial, the 
combination of cediranib with platinum-based chemotherapy significantly improved PFS but OS 
was not significantly improved; notably there was evidence of nonproportional hazards [19].  
Finally, in the MITO-11 phase 2 clinical trial pazopanib plus weekly paclitaxel improved PFS 
versus paclitaxel alone without significantly prolonging OS [33].  Our results are also consistent 
with those that have previously demonstrated activity of trebananib in ovarian cancer.  
Trebananib plus weekly paclitaxel has previously been shown to improve PFS and ORR (but not 
OS) compared with placebo plus paclitaxel in patients with recurrent ovarian cancer in the 
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TRINOVA-1 study [24,25].  Duration of response, an endpoint that is independent of the time of 
treatment initiation, was longer in the trebananib arm both in this study and in the TRINOVA-1 
study (unpublished observation, 7.1 months [95%CI, 5.6‒8.2] for trebananib versus 5.1 months 
[95%CI, 3.8‒5.6] for placebo).  Interestingly, we found that the odds ratio for response 
(trebananib:placebo) was higher among patients with ascites at baseline compared with those 
without ascites at baseline.  This finding is consistent with subgroup analysis of the TRINOVA-1 
study  [35] and with analysis of studies evaluating bevacizumab in ovarian cancer [36-38].  
Together, these results suggest that patients with ascites may have disease that is particularly 
susceptible to treatment with antiangiogenic agents [39,40].   
In summary, although this study did not meet its primary endpoint of prolongation of 
PFS, trebananib added to PLD improved ORR and duration of response [25].  No new safety 
signals were identified with the combination of trebananib plus PLD.  
Marth et al  Page 14 of 37 
ACKNOWLEDGMENTS 
The authors thank Jennifer Venzie, PhD (Complete Healthcare Communications, LLC, Chadds 
Ford, PA), whose work was funded by Amgen Inc., for assistance in the preparation of this 
manuscript. 
ROLE THE FUNDING SOURCE 
This work was funded by Amgen Inc. 
CONFLICT OF INTEREST STATMENT 
I Vergote: educational grant from Amgen (paid to institution) and honoraria for advisory boards 
from Amgen; A Clamp: honoraria from Roche and honoraria and research funding from 
AstraZeneca; C Kurzeder: personal fees from Amgen, Roche and AstraZeneca; N. Colombo:  
advisory board participation for Amgen;  P Vuylsteke:  travel grants and advisory fees from 
Amgen; D Lorusso:  participation in advisory boards for Roche, AstraZeneca and Pharmamar; G 
Rustin:  participation on advisory boards for Amgen and Oxigene; RM Wenham:  steering 
committee honoraria and meeting travel expenses paid by Amgen; BJ Monk: grants and/or 
personal fees paid to his institution from Amgen, Novartis, Eli Lilly Genentech, Janssen/Johnson 
& Johnson, Array, TESARO and Morphotek; honoraria for speaker bureaus from AstraZeneca, 
Myriad, Janssen/Johnson & Johnson and Roche/Genentech; consultant for Roche/Genentech, 
Merck, TESARO, AstraZeneca, Gradalis, Cerulean, Amgen, Vermillion, ImmunoGen, Pfizer, 
Bayer, NuCana, Insys, GlaxoSmithKline, Verastem, and Clovis; H Ma and FD Vogl:  employees 
of Amgen and owners of stock in Amgen; BA Bach:  employee of Amgen, ownership of stock in 
Amgen, and inventor, with patent application pending; C Marth, G Scambia, W Oberaigner, R 
Berger, M Hall, V Renard, S Pignata, R Kristeleit, S Altintas, M Raza Mirza, PC Fong, A Oza: 
none. 
Marth et al  Page 15 of 37 
AUTHOR CONTRIBUTIONS 
Study concepts: C Marth, I Vergote, R Berger, C Kurzeder, D Lorusso, S Pignata, G Rustin and 
BJ Monk 
Study design: C Marth, I Vergote, R Berger, C Kurzeder, G Rustin, RM Wenham and BJ Monk 
Data acquisition: C Marth, I Vergote, A Clamp, R Berger, C Kurzeder, D Lorusso, M Hall, S 
Pignata, R Kristeleit, G Rustin, RM Wenham, PC Fong, FD Vogl and BA Bach  
Quality control of data and algorithms: C Marth, R Berger R Kristeleit, FD Vogl and BA Bach 
Data analysis and interpretation: all authors 
Statistical analysis: H Ma 
Manuscript preparation, editing, and review: all authors 
 
  
Marth et al  Page 16 of 37 
REFERENCES 
[1] NCCN clinical practice guidelines in oncology: ovarian cancer v.2.2015. Fort 
Washington, PA: National Comprehensive Cancer Network; 2015. 
[2] Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of 
advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013;10:211-24. doi: 
10.1038/nrclinonc.2013.5. 
[3] Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol 2006;17 Suppl 
5:v181-7. doi: 10.1093/annonc/mdj978. 
[4] Rose PG, Maxson JH, Fusco N, Mossbruger K, Rodriguez M. Liposomal doxorubicin in 
ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-
agent dosages. Gynecol Oncol 2001;82:323-8. doi: 10.1006/gyno.2001.6272. 
[5] Campos SM, Penson RT, Mays AR, et al. The clinical utility of liposomal doxorubicin in 
recurrent ovarian cancer. Gynecol Oncol 2001;81:206-12. doi: 10.1006/gyno.2000.5980. 
[6] Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Phase 2 trial of 
liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and 
fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 
2000;78:369-72. doi: 10.1006/gyno.2000.5921. 
[7] Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in 
refractory ovarian cancer: antitumor activity and toxicity modification by liposomal 
encapsulation. J Clin Oncol 1997;15:987-93. 
[8] Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women 
treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 
randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 
2004;95:1-8. doi: 10.1016/j.ygyno.2004.07.011. 
[9] Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 
2002;29:15-8. doi: 10.1016/S0093-7754(02)70065-1. 
Marth et al  Page 17 of 37 
[10] Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and 
homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009;10:165-
77. doi: 10.1038/nrm2639. 
[11] Gavalas NG, Liontos M, Trachana SP, et al. Angiogenesis-related pathways in the 
pathogenesis of ovarian cancer. Int J Mol Sci 2013;14:15885-909. doi: 
10.3390/ijms140815885. 
[12] Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy 
for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized 
phase III trial. J Clin Oncol 2014;32:1302-8. doi: 10.1200/JCO.2013.51.4489. 
[13] Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-
controlled phase III trial of chemotherapy with or without bevacizumab in patients with 
platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube 
cancer. J Clin Oncol 2012;30:2039-45. doi: 10.1200/JCO.2012.42.0505. 
[14] Coleman RL, Brady MF, Herzog TJ, et al. A phase III randomized controlled clinical trial 
of carboplatin and paclitaxel alone or in combination with bevacizumab followed by 
bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent 
ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 
0213) [abstract]. Gynecol Oncol 2015;137:3-4. doi: 10.1016/j.ygyno.2015.01.005. 
[15] Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary 
treatment of ovarian cancer. N Engl J Med 2011;365:2473-83. doi: 
10.1056/NEJMoa1104390. 
[16] Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. 
N Engl J Med 2011;365:2484-96. doi: 10.1056/NEJMoa1103799. 
[17] Du Bois A, Kristensen G, Ray-Coquard I, et al. AGO-OVAR 12: A randomized placebo-
controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy +/- 
nintedanib for advanced ovarian cancer [abstract]. Int J Gyn Cancer 2013;23:PL01. 
Marth et al  Page 18 of 37 
[18] du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy 
of ovarian cancer. J Clin Oncol 2014;32:3374-82. doi: 10.1200/JCO.2014.55.7348. 
[19] Ledermann JA, Embleton AC, Raja F, et al. Cediranib in patients with relapsed platinum-
sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 
3 trial. The Lancet;387:1066-74. doi: http://dx.doi.org/10.1016/S0140-6736(15)01167-8. 
[20] Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival 
and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without 
bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 
2015;139:10-6. doi: 10.1016/j.ygyno.2015.08.004. 
[21] Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective 
inhibition of angiopoietin-2. Cancer Cell 2004;6:507-16. doi: 10.1016/j.ccr.2004.09.030. 
[22] Coxon A, Bready J, Min H, et al. Context-dependent role of angiopoietin-1 inhibition in 
the suppression of angiogenesis and tumor growth: implications for AMG 386, an 
angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2010;9:2641-51. doi: 
10.1158/1535-7163.MCT-10-0213. 
[23] Vergote I, Schilder RJ, Pippitt Jr CH, et al. A phase 1b study of trebananib in 
combination with pegylated liposomal doxorubicin or topotecan in women with recurrent 
platinum-resistant or partially platinum-sensitive ovarian cancer. Gynecol Oncol 
2014;135:25-33. doi: 10.1016/j.ygyno.2014.07.003. 
[24] Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled 
phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent 
ovarian cancer. J Clin Oncol 2012;30:362-71. doi: 10.1200/JCO.2010.34.3178. 
[25] Monk BJ, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for 
recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, 
placebo-controlled phase 3 trial. Lancet Oncol 2014;15:799-808. doi: 10.1016/S1470-
2045(14)70244-X. 
Marth et al  Page 19 of 37 
[26] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. doi: 
10.1016/j.ejca.2008.10.026. 
[27] Vergote I, Pujade-Lauraine E, Pignata S, et al. European Network of Gynaecological 
Oncological Trial Groups' requirements for trials between academic groups and 
pharmaceutical companies. Int J Gynecol Cancer 2010;20:476-8. doi: 
10.1111/IGC.0b013e3181d3caa8. 
[28] Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events 
v3.0 (CTCAE). Available at: 
http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf. 
Accessed December 2, 2015. 
[29] Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy 
scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9. 
[30] Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72. 
[31] Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-
based residuals. Biometrika 1993;80:557-72. doi: 10.1093/biomet/80.3.557. 
[32] Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor 
(VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis 
inhibitors; a review. Eur J Cancer 2006;42:3127-39. 
[33] Pignata S, Lorusso D, Scambia G, et al. MITO-11: A randomized multicenter phase II 
trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -
refractory advanced ovarian cancer (AOC). ASCO Meeting Abstracts 2014;32:5503. 
[34] Poveda AM, Selle F, Hilpert F, et al. Bevacizumab Combined With Weekly Paclitaxel, 
Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent 
Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III 
AURELIA Trial. J Clin Oncol 2015;33:3836-8. doi: 10.1200/JCO.2015.63.1408. 
Marth et al  Page 20 of 37 
[35] Monk BJ, Poveda A, Vergote I, et al. Impact of trebananib plus weekly paclitaxel on 
overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results 
from the phase III TRINOVA-1 study. ASCO Meeting Abstracts 2015;33:5503. 
[36] Poveda AM, Selle F, Hilpert F, et al. Bevacizumab Combined With Weekly Paclitaxel, 
Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent 
Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III 
AURELIA Trial. J Clin Oncol 2015;33:3836-8. doi: 10.1200/jco.2015.63.1408. 
[37] Ferriss JS, Java JJ, Bookman MA, et al. Ascites predicts treatment benefit of 
bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and 
peritoneal cancers: An NRG Oncology/GOG study. Gynecol Oncol 2015;139:17-22. doi: 
10.1016/j.ygyno.2015.07.103. 
[38] Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without 
bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival 
results of a phase 3 randomised trial. Lancet Oncol 2015;16:928-36. doi: 10.1016/s1470-
2045(15)00086-8. 
[39] Sangisetty SL, Miner TJ. Malignant ascites: a review of prognostic factors, 
pathophysiology and therapeutic measures. World J Gastrointest Surg 2012;4:87-95. 
[40] Smolle E, Taucher V, Haybaeck J. Malignant ascites in ovarian cancer and the role of 
targeted therapeutics. Anticancer Res 2014;34:1553-61. 
 
  
Marth et al  Page 21 of 37 
Table 1. Demographics and Baseline Clinical Characteristics 
 
Trebananib Plus PLD 
n=114 
Placebo Plus PLD 
n=109 
Median (range) age, y 61 (53–68) 60 (53–66) 
Race/ethnicity, n (%) 
 White 
 Asian 










2 (2)  
3 (3) 










41 (38)  
1 (1) 
Primary tumor type, n (%) 
 Ovarian cancer 
 Peritoneal carcinoma 
























6 (6)  
1 (1) 
13 (12)  
Histologic grade, n (%) 
 Well differentiated 
 Moderately differentiated 























23 (21)  
Platinum-free interval, n (%) 
 6 months 







Prior antiangiogenic therapy, n (%) 20 (18) 16 (15) 
Measurable disease at baseline, n (%) 99 (87) 94 (86) 
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Region, n (%) 
 North America 
 Western Europe/Australasia 









GOG=Gynecologic Oncology Group; IQR=interquartile range; PLD=pegylated liposomal 
doxorubicin. 
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Table 2.  Piecewise Cox Model for PFS Using 16-Week Intervals (Prespecified) 
Time Interval, Week HR* 95% CI Weight† P Value 
0–16 0.59 0.34–1.01 0.31 0.05 
16–32 1.07 0.60–1.92 0.27 0.81 
32–48 1.00 0.58–1.72 0.31 0.99 
48–64 1.55 0.56–4.29 0.09 0.40 
≥64 2.38 0.41–13.95 0.03 0.34 
HR=hazard ratio; PFS=progression-free survival. 
*HRs within each time interval are presented as trebananib group: placebo group; an HR <1.0 
indicates a lower average event rate and a longer time to event for the trebananib group relative 
to the placebo group. 
†Weight is inversely proportional to the variance of each interval estimate.  Values do not sum to 
1.00 due to rounding. 
 
Marth et al  Page 24 of 37 








Objective response rate, % (95% CI) 46 (36–57) 21 (14–31) 
Best response assessment, n (%)   
 Complete response 1 (1) 2 (2) 
 Partial response 45 (46) 18 (19) 
 Stable disease 28 (28) 50 (53) 
 Progressive disease 14 (14) 16 (17) 
Unevaluable* 1 (1) 1(1) 
Not done† 10 (10) 7 (7) 
PLD=pegylated liposomal doxorubicin. 
*Patients for whom imaging was not performed at the scheduled assessment of response.  †Patients with a response assessment of 
complete response, partial response, or stable disease before scheduled first assessment of response without an additional 
assessment of a response.  
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 Any Grade ≥3 Grade ≥4 Fatal Any Grade ≥3 Grade ≥4 Fatal 
All treatment-emergent adverse events, n (%) 113 (100) 87 (77) 15 (13) 7 (6) 108 (100) 78 (72) 21 (19) 7 (6) 
Treatment-emergent adverse events occurring 
in ≥10% of patients in either treatment arm, n 
(%) 
        
 Palmar-plantar erythrodysesthesia* 69 (61)  22 (20) 0 (0) 0 (0) 61 (57) 13 (12)  0 (0) 0 (0) 
 Localized edema* 69 (61) 5 (4) 0 (0) 0 (0) 34 (32)  2(2) 0 (0) 0 (0) 
 Nausea 67 (59) 7 (6) 0 (0) 0 (0) 62 (57) 5 (5) 0 (0) 0 (0) 
 Fatigue* 60 (53) 8 (7) 0 (0) 0 (0) 48 (44) 5 (5) 1 (1) 0 (0) 
 Stomatitis 58 (51) 7 (6) 1 (1) 0 (0) 55 (51) 6 (6) 0 (0) 0 (0) 
 Vomiting* 51 (45) 7 (6) 0 (0) 0 (0) 36 (33) 6 (6) 0 (0) 0 (0) 
 Abdominal pain* 35 (31) 7 (6) 0 (0) 0 (0) 41 (38) 5 (5) 0 (0) 0 (0) 
 Constipation 39 (34) 2 (2) 0 (0) 0 (0) 35 (32) 2 (2) 0 (0) 0 (0) 
 Diarrhea 33 (29) 3 (3) 1 (1) 1 (1) 28 (26) 5 (5) 0 (0) 0 (0) 
 Ascites* 33 (29) 24 (21) 0 (0) 0 (0) 10 (9) 7 (7) 0 (0) 0 (0) 
 Rash 31 (27) 2 (2) 0 (0) 0 (0) 28 (26) 2 (2) 0 (0) 0 (0) 
 Mucosal inflammation* 20 (18) 1 (1) 0 (0) 0 (0) 26 (24) 2 (2) 0 (0) 0 (0) 
 Decreased appetite 27 (24) 1 (1) 0 (0) 0 (0) 23 (21) 2 (2) 0 (0) 0 (0) 
 Dyspnea 24 (21) 5 (4) 0 (0) 0 (0) 18 (17) 3 (3) 2 (2) 1 (1) 
 Hypokalemia* 24 (21) 8 (7) 1( 1) 0 (0) 11 (10) 2 (2) 1 (1) 0 (0) 
 Cough* 23 (20) 0 (0) 0 (0) 0 (0) 16 (15) 0 (0) 0 (0) 0 (0) 
 Neutropenia* 15 (13)  8 (7) 1 (1) 0 (0) 22 (20) 13 (12) 4 (4) 0 (0) 
 Dyspepsia 21 (21) 1 (1) 0 (0) 0 (0) 16 (15) 0 (0) 0 (0) 0 (0) 
 Alopecia* 21 (19) 0 (0) 0 (0) 0 (0) 12 (11) 0 (0) 0 (0) 0 (0) 








 Any Grade ≥3 Grade ≥4 Fatal Any Grade ≥3 Grade ≥4 Fatal 
 Pyrexia 20 (18) 1 (1) 0 (0) 0 (0) 18 (17) 0 (0) 0 (0) 0 (0) 
 Back pain* 11 (10) 0 (0) 0 (0) 0 (0) 18 (17) 0 (0) 0 (0) 0 (0) 
 Abdominal pain, upper 17 (15) 0 (0) 0 (0) 0 (0) 17 (16)  2 (2) 0 (0) 0 (0) 
 Headache 15 (13) 3 (3) 0 (0) 0 (0) 16 (15) 1 (1) 0 (0) 0 (0) 
 Pleural effusion 16 (14) 6 (5) 0 (0) 0 (0) 11 (10) 4 (4) 1 (1) 1 (1) 
 Dizziness 12 (11) 0 (0) 0 (0) 0 (0) 15 (14) 1 (1) 0 (0) 0 (0) 
 Anemia 11 (10) 3 (3) 1 (1) 0 (0) 15 (14) 4 (4) 0 (0) 0 (0) 
 Oropharyngeal pain 15 (13) 0 (0) 0 (0) 0 (0) 10 (9) 0 (0) 0 (0) 0 (0) 
 Asthenia 9 (8) 0 (0) 0 (0) 0 (0) 13 (12) 3 (3) 0 (0) 0 (0) 
 Dry skin 9 (8) 0 (0) 0 (0) 0 (0) 13 (12) 0 (0) 0 (0) 0 (0) 
 Weight decreased* 4 (4) 0 (0) 0 (0) 0 (0) 12 (11) 2 (2) 0 (0) 0 (0) 
 Nasopharyngitis 12 (11) 0 (0) 0 (0) 0 (0) 11 (10) 0 (0) 0 (0) 0 (0) 
 Insomnia 11 (10) 0 (0) 0 (0) 0 (0) 11 (10) 1 (1) 0 (0) 0 (0) 
 Hypertension 12 (11) 3 (3) 0 (0) 0 (0) 9 (8) 0 (0) 0 (0) 0 (0) 
 Muscle spasms 9 (8) 0 (0) 0 (0) 0 (0) 11 (10) 0 (0) 0 (0) 0 (0) 
 Neuropathy, peripheral 8 (7) 0 (0) 0 (0) 0 (0) 11 (10) 0 (0) 0 (0) 0 (0) 
 Abdominal distension 7 (6) 0 (0) 0 (0) 0 (0) 11 (10) 2 (2) 0 (0) 0 (0) 
 Skin hyperpigmentation 7 (6) 0 (0) 0 (0) 0 (0) 11 (10) 0 (0) 0 (0) 0 (0) 
 Pain in extremity* 12 (11) 0 (0) 0 (0) 0 (0) 5 (5) 0 (0) 0 (0) 0 (0) 
 Pruritus 11 (10) 0 (0) 0 (0) 0 (0) 8 (7) 0 (0) 0 (0) 0 (0) 
 Upper respiratory tract infection 11 (10) 1 (1) 0 (0) 0 (0) 6 (6) 0 (0) 0 (0) 0 (0) 
 Hypomagnesaemia* 11 (10) 4 (4) 0 (0) 0 (0) 3 (3) 1 (1) 0 (0) 0 (0) 
PLD=pegylated liposomal doxorubicin. 
*Indicates a ≥5% difference in incidence between the trebananib plus PLD arm and the placebo plus PLD arm. 
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FIGURES 
Figure 1. Disposition of patients in the study.  IV=intravenous; PLD=pegylated liposomal 
doxorubicin; QW=once weekly. 
Figure 2. (A) Kaplan-Meier analysis of progression-free survival. (B)  Kaplan-Meier 
analysis of overall survival.  HR=hazard ratio; PFS=progression-free survival; 
OS=overall survival; PLD=pegylated liposomal doxorubicin.  
Figure 3. (A) Kaplan-Meier analysis of duration of response.  (B) Objective response in 
patient subgroups defined by baseline characteristics.  (C) Maximum change in 
tumor size from baseline to postbaseline nadir (measurable disease at baseline) 
in individual patients receiving PLD plus trebananib or PLD plus placebo. 
PLD=pegylated liposomal doxorubicin; SLD=sum of longest diameter.  
CR=complete response; PR=partial response; SD=stable disease; 
PD=progressive disease; NE=not evaluated.  *Number of patients with an 
objective response (complete or partial response per modified RECIST version 
1.1).  †Arrows indicates an inestimable confidence interval for the upper or lower 
bounds for the plot.   
Figure 1. 
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Other reasons (n=2) 
Ongoing (n=8)
Randomized (n=223)
Arm 1 – trebananib 15 mg/kg QW + PLD (n=114)
Received trebananib 15 mg/kg IV QW (n=112)
Did not  receive trebananib 15 mg/kg QW (n=2)
Did not  receive PLD (n=2)





Other reasons (n=2) 
Ongoing (n=8)   
Arm 2 – placebo IV QW + PLD (n=109) 
Received placebo IV QW (n=108)
Did not receive placebo IV QW (n=1)
Did not  receive PLD (n=1)
Included in efficacy analysis (n=114)
Excluded from efficacy analysis (n=0)
Included in safety analysis (n=113)
Excluded from safety analysis (n=1)
Included in efficacy analysis (n=109)
Excluded from efficacy analysis (n=0)
Included in safety analysis (n=108)
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Figure 2 
A  Progression-Free Survival 
 
B  Overall Survival 
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ENGOT-ov-6/TRINOVA-2:  Randomized, Double-Blind, Phase 3 Study of Pegylated 
Liposomal Doxorubicin Plus Trebananib or Placebo in Women With Recurrent Partially 
Platinum-Sensitive or Resistant Ovarian Cancer 
Christian Marth, Ignace Vergote, Giovanni Scambia, Willi Oberaigner, Andrew Clamp, Regina 
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Supplemental Figure 1.  Health-related quality of life among patients with ascites receiving 
paclitaxel plus placebo or trebananib plus placebo at week 1 (baseline) through week 25.  
Health-related quality of life was evaluated with (A) FACT-O, (B) OCS, (C) EQ-5D, and (D) EQ-
5D VAS scores over time. FACT-O, Functional Assessment of Cancer Therapy–Ovary; OCS, 
ovarian cancer–specific subscale; VAS, visual analogue scale; IQR, interquartile range. 
A.  FACT-O 
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D. EQ-5D VAS 
 
